Taking in addition the proven safety of high dose systemic administration of MV in multiple myeloma patients into account [25] we expect that targeting CD30 results in safe products exerting, if at all, only subtle side-effects. The gene discussed is TNFRSF8; the disease is AL amyloidosis.